Navigation Links
Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
Date:3/22/2010

EXTON, Pa., March 22 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer of West Pharmaceutical Services, Inc., has joined Kensey Nash's Board of Directors.

Dr. Morel has served as Chief Executive Officer of West Pharmaceutical Services, Inc. since April 2002 and Chairman of the Board since March 2003.  He joined West in 1992 as Director of Research and Development and was promoted to Vice President R&D in 1993.  In this role, Dr. Morel spearheaded West's efforts to develop novel and proprietary drug delivery technologies. From 1998 to 2001, he served as President of several of West's divisions and in April 2001 Dr. Morel became President and Chief Operating Officer.  

Prior to joining West Pharmaceutical, Dr. Morel developed and managed a broad range of programs involving advanced materials for aerospace, biomedical and pharmaceutical applications for several companies.  Dr. Morel holds a BS degree in Engineering from Lafayette College, an MS in Materials Science and a Ph.D. in Materials Science and Veterinary Medicine from Cornell University.  He has received several awards and honors including becoming a fellow for the American Institute for Medical & Biologic Engineering.  In addition to Kensey Nash's Board, Dr. Morel serves as a Director and Trustee of numerous non-profit organizations including the Fox Chase Cancer Center.

"Dr. Morel's extensive business experience and materials science knowledge will be a tremendous asset to our Board and our company," commented Joseph W. Kaufmann, President and CEO of Kensey Nash Corporation.  "His outstanding leadership as Chairman and CEO of West Pharmaceutical is well documented and we are fortunate to have someone of his stature on our Board.  I am very pleased to welcome him as a member," he concluded.

"Over the past twenty-five years Kensey Nash has developed a broad range of innovative products and materials that have benefited patients worldwide.  I am pleased to have the opportunity to join the Board and look forward to working with the current Directors and talented management team to achieve the company's strategic objectives," Dr. Morel commented.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology.  The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials.  The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopedic, sports medicine, spine, endovascular and general surgery markets.

SOURCE Kensey Nash Corporation

Back to top

RELATED LINKS
http://www.kenseynash.com

'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Kensey Nash Announces $30 Million Share Buyback
7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 2017  Rigel Pharmaceuticals (Nasdaq: RIGL ) ... 16, 2017 the Compensation Committee of Rigel,s Board of ... purchase an aggregate of 214,000 shares of common stock ... to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, ... into employment with Rigel, in accordance with NASDAQ Listing ...
(Date:1/16/2017)... -- CBDRx, the world,s premiere nutraceutical hemp company, is ... extract to Veteran,s groups across the country. ... to Veteran,s groups across the United States.  Passion is ... world and through their passion, CBDRx honors our Veterans ... hemp extract available. ...
(Date:1/15/2017)... -- Le conseil d,administration de SurgaColl Technologies Ltd., ... la régénération de tissus humains, annonce la nomination de ... effet immédiat. ... Bill est un dirigeant expérimenté à l,international dans l,industrie ... générale et de direction au sein de sociétés internationales spécialisées ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... in the Aesthetic Surgery Journal , the official journal of The American ... on lower eyelid retraction surgery. The procedure is designed to correct drooping, retracted ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Chief Executive Officer of the medical device company, effective immediately. , “This is ... “Kevin has a strong track record in medical device market development and ...
(Date:1/15/2017)... ... 2017 , ... Whole Health Supply, LLC is announcing the release of an updated version of ... purchase. , The 2017 edition has wide jaws that will accommodate nails up to ... well as diabetics. This handle is reinforced for extra strength when pressing down on dense ...
(Date:1/15/2017)... ... , ... Wondering where to go this Valentine's Day? Well, there is a ... romantic, lobster feast in the comfort of your own home. Lobster Gram is introducing ... be featured until February 15th, 2017. , Romantic Dinner one is Lobster Gram's ...
(Date:1/14/2017)... ... 2017 , ... According to a December 9 article ... the risk of type 2 diabetes, Alzheimer’s, and cardiovascular disease. Southern California based ... linked to a Mediterranean diet are only some of the many reasons that ...
Breaking Medicine News(10 mins):